FDA OKs Prolastin-C for AAT Deficiency
- By BSTQ Staff
Prolastin-C has been approved by the Food and Drug Administration for the treatment of alpha1-antitrypsin (AAT)deficiency, a genetic condition in which low levels of this essential protein can result in emphysema. Manufactured by Talecris Biotherapeutics, Prolastin-C’s active protein increases or “augments” protein levels in AAT-deficient patients. Clinical studies have shown that Prolastin-C and Prolastin are equally effective at raising AAT levels in the blood, and that the adverse event profile of Prolastin-C is consistent with that of Prolastin.However, Prolastin-C delivers twice the active protein per milliliter as Prolastin, cutting infusion volume and time in half when given at a recommended rate of 0.08 mL/kg/min.